LIVE NCPD WEBINARS: October 14, 2021, 5:00 PM – 6:00 PM Eastern Time

Fall Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Chronic Lymphocytic Leukemia

Event moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Thursday, October 14, 2021, 5:00 PM – 6:00 PM ET

Anthony R Mato, MD, MSCE
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York
Corinne Hoffman, MS, APRN-CNP, AOCNP
Nurse Practitioner, Hematology
The James Comprehensive Cancer Center
The Ohio State University Wexner Medical Center
Columbus, Ohio


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Topics to Be Discussed

  • Overview of chronic lymphocytic leukemia (CLL) incidence and prognosis, patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting patient care
  • Role of cytogenetics and molecular profiling in prognostication, risk stratification and treatment decision-making for CLL; 17p deletion, TP53 and IGHV gene mutations
  • Mechanism of action, effectiveness and incorporation into therapy of the approved Bruton tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib, alone or in combination with an anti-CD20 antibody, for newly diagnosed or relapsed/refractory CLL; comparative tolerability profiles and management of side effects
  • Integration of the Bcl-2 inhibitor venetoclax in combination with an anti-CD20 antibody into therapy for newly diagnosed or relapsed/refractory CLL; risk of tumor lysis syndrome and preemptive measures, including dose ramp-up; role of minimal residual disease in determining treatment duration
  • Management of multiple regimen-relapsed CLL; mechanism of action, effectiveness and incorporation into therapy of the PI3K inhibitors idelalisib and duvelisib; common toxicities and mitigation of side effects
  • Novel agents under investigation for CLL, including the noncovalent BTK inhibitor LOXO-305; mechanism of action and potential clinical role
  • Efficacy of CAR T-cell therapy for patients with CLL in ongoing clinical trials; spectrum, incidence and management of associated adverse events

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Apply available clinical information and research data to the therapeutic and supportive care of patients with CLL.
  • Appreciate the importance of clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status in the selection of systemic therapy for patients with newly diagnosed CLL.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase inhibition with ibrutinib or acalabrutinib compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and discern how this strategy can be optimally integrated into nonresearch treatment.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how this regimen can be appropriately integrated into treatment decision-making.
  • Recognize how published research data, prior therapeutic exposure and the results of biomarker analyses can influence the selection and sequencing of therapy, and use this information to counsel patients with relapsed/refractory CLL about the rationale for individualized treatment recommendations.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with systemic therapies commonly used in the management of CLL, in order to support quality of life and continuation of therapy.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Mato has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms HoffmanAdvisory Board: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Pharmacyclics LLC, an AbbVie Company.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.